Sclerosing Cholangitis Epidemiology and Etiology

Overview

Journal J Gastrointest Surg

Specialty Gastroenterology

Date 2007 Oct 25

PMID 17957439

Citations 4

Authors

Konstantinos N Lazaridis

Affiliations

Soon will be listed here.

Abstract

Sclerosing cholangitis represents a spectrum of chronic biliary diseases that either has an unknown etiology (i.e., primary) or is caused by identifiable insults to the biliary tree (i.e., secondary). To date, the epidemiology of primary sclerosing cholangitis has been appraised; however, its etiology continues to be unclear. In contrast, the etiology of secondary sclerosing cholangitis is always known, but the epidemiology of this clinical entity is difficult to study.

Citing Articles

Secondary sclerosing cholangitis as a complication of severe COVID-19: A case report and review of the literature.

Klindt C, Jensen B, Brandenburger T, Feldt T, Killer A, Schimmoller L Clin Case Rep. 2021; 9(5):e04068.

PMID: 34084492 PMC: 8142800. DOI: 10.1002/ccr3.4068.

Pathophysiologic implications of innate immunity and autoinflammation in the biliary epithelium.

Strazzabosco M, Fiorotto R, Cadamuro M, Spirli C, Mariotti V, Kaffe E Biochim Biophys Acta Mol Basis Dis. 2017; 1864(4 Pt B):1374-1379.

PMID: 28754453 PMC: 5785585. DOI: 10.1016/j.bbadis.2017.07.023.

Macrophage Depletion Attenuates Extracellular Matrix Deposition and Ductular Reaction in a Mouse Model of Chronic Cholangiopathies.

Best J, Verhulst S, Syn W, Lagaisse K, Van Hul N, Heindryckx F PLoS One. 2016; 11(9):e0162286.

PMID: 27618307 PMC: 5019458. DOI: 10.1371/journal.pone.0162286.

Isolated Mass-Forming IgG4-Related Cholangitis as an Initial Clinical Presentation of Systemic IgG4-Related Disease.

Kim S, Bae H, Choi M, Kim B, Heo J, Kim H J Pathol Transl Med. 2016; 50(4):300-5.

PMID: 26755360 PMC: 4963967. DOI: 10.4132/jptm.2015.12.01.

References

Yang X, Cullen S, Li J, Chapman R, Jewell D . Susceptibility to primary sclerosing cholangitis is associated with polymorphisms of intercellular adhesion molecule-1. J Hepatol. 2004; 40(3):375-9. DOI: 10.1016/j.jhep.2003.11.009. View

Ludwig J, Barham S, Larusso N, ELVEBACK L, Wiesner R, McCALL J . Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology. 1981; 1(6):632-40. DOI: 10.1002/hep.1840010612. View

Gossard A, Angulo P, Lindor K . Secondary sclerosing cholangitis: a comparison to primary sclerosing cholangitis. Am J Gastroenterol. 2005; 100(6):1330-3. DOI: 10.1111/j.1572-0241.2005.41526.x. View

Eri R, Jonsson J, Pandeya N, Purdie D, Clouston A, Martin N . CCR5-Delta32 mutation is strongly associated with primary sclerosing cholangitis. Genes Immun. 2004; 5(6):444-50. DOI: 10.1038/sj.gene.6364113. View

Bergquist A, Lindberg G, Saarinen S, Broome U . Increased prevalence of primary sclerosing cholangitis among first-degree relatives. J Hepatol. 2005; 42(2):252-6. DOI: 10.1016/j.jhep.2004.10.011. View

Bambha K, Kim W, Talwalkar J, Torgerson H, Benson J, Therneau T . Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology. 2003; 125(5):1364-9. DOI: 10.1016/j.gastro.2003.07.011. View

Mendes F, Jorgensen R, Keach J, Katzmann J, Smyrk T, Donlinger J . Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2006; 101(9):2070-5. DOI: 10.1111/j.1572-0241.2006.00772.x. View

Palmer K, Duerden B, HOLDSWORTH C . Bacteriological and endotoxin studies in cases of ulcerative colitis submitted to surgery. Gut. 1980; 21(10):851-4. PMC: 1419372. DOI: 10.1136/gut.21.10.851. View

Larusso N, Wiesner R, Ludwig J, MacCarty R, Beaver S, Zinsmeister A . Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology. 1988; 95(4):1036-42. DOI: 10.1016/0016-5085(88)90180-1. View

10.

Satsangi J, Chapman R, Haldar N, Donaldson P, Mitchell S, Simmons J . A functional polymorphism of the stromelysin gene (MMP-3) influences susceptibility to primary sclerosing cholangitis. Gastroenterology. 2001; 121(1):124-30. DOI: 10.1053/gast.2001.25527. View

11.

Angulo P, Peter J, Gershwin M, DeSotel C, Shoenfeld Y, Ahmed A . Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol. 2000; 32(2):182-7. DOI: 10.1016/s0168-8278(00)80061-6. View

12.

Chapman R, Varghese Z, Gaul R, Patel G, Kokinon N, Sherlock S . Association of primary sclerosing cholangitis with HLA-B8. Gut. 1983; 24(1):38-41. PMC: 1419910. DOI: 10.1136/gut.24.1.38. View

13.

Muratori P, Muratori L, Guidi M, MacCariello S, Pappas G, Ferrari R . Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clin Exp Immunol. 2003; 132(3):473-6. PMC: 1808737. DOI: 10.1046/j.1365-2249.2003.02166.x. View

14.

Donaldson P, Farrant J, Wilkinson M, Hayllar K, Portmann B, Williams R . Dual association of HLA DR2 and DR3 with primary sclerosing cholangitis. Hepatology. 1991; 13(1):129-33. View

15.

Spurkland A, Saarinen S, Boberg K, Mitchell S, Broome U, Caballeria L . HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens. 1999; 53(5):459-69. DOI: 10.1034/j.1399-0039.1999.530502.x. View

16.

Norris S, Kondeatis E, Collins R, Satsangi J, Clare M, Chapman R . Mapping MHC-encoded susceptibility and resistance in primary sclerosing cholangitis: the role of MICA polymorphism. Gastroenterology. 2001; 120(6):1475-82. DOI: 10.1053/gast.2001.24041. View

17.

Erkelens G, Vleggaar F, Lesterhuis W, van Buuren H, van der Werf S . Sclerosing pancreato-cholangitis responsive to steroid therapy. Lancet. 1999; 354(9172):43-4. DOI: 10.1016/s0140-6736(99)00603-0. View

18.

Quigley E, Larusso N, Ludwig J, MacSween R, Birnie G, Watkinson G . Familial occurrence of primary sclerosing cholangitis and ulcerative colitis. Gastroenterology. 1983; 85(5):1160-5. View

19.

Lazaridis K, Strazzabosco M, LaRusso N . The cholangiopathies: disorders of biliary epithelia. Gastroenterology. 2004; 127(5):1565-77. DOI: 10.1053/j.gastro.2004.08.006. View

20.

Mitchell S, Grove J, Spurkland A, Boberg K, Fleming K, Day C . Association of the tumour necrosis factor alpha -308 but not the interleukin 10 -627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis. Gut. 2001; 49(2):288-94. PMC: 1728404. DOI: 10.1136/gut.49.2.288. View